CDK4 and hepatocellular carcinoma: Kinase AMPK was suggested as a target of inhibition for palbociclib, independently of CDK4/6, in hepatocellular carcinoma cells, while the two other inhibitors, abemaciclib and ribociclib had no inhibitory effect in this kinase [86].